Although preclinical work for CROs has fallen flat in recent quarters, Covance is looking to take advantage of the industry’s shift to early biologic developments and lead optimization.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!PRINCETON, N.J., May 13, 2013 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present a…
Covances 10 percent growth in Q1 2013 compared to the same quarter last year was driven mostly by its central laboratories business and has caused a boost in its revenue targets for the rest of the ye…
Covance’s 10 percent growth in Q1 2013 compared to the same quarter last year was driven mostly by its central laboratories business and has caused a boost in its revenue targets for the rest of…
